Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.
Joana Correia, Exogenus’s co-founder, CEO and CSO is an invited speaker at the IX BiotechHealth Annual Symposium, organized by i3S and taking place on June 28th 2022. Joana will be taking...
Today the final event of the InnoCore Challenge took place in Granada, Spain. Teams of MSc and PhD students were challenged to propose solutions for real problems faced by companies....
Exogenus Therapeutics announces collaboration with Boehringer Ingelheim to explore the use of extracellular vesicles in regenerative medicine applications